R & D Results
The research institute has applied for more than 3,500 patents, and more than 1,500 foreign patents; the total number of pharmaceutical patents, compound patents, compound PCT patents, patent application growth rate and patent quality applied by HEC Pharma each year rank in the forefront of China.
HEC has obtained 2 national-level laboratories, and undertakes the research and development of 29 major national new drug projects. It has won the "Innovation Team" of Guangdong Province for six consecutive times, and has received a total of more than 1.5 billion yuan in R&D funds. The total investment of HEC Research Institute in the past 18 years has exceeded 18 billion yuan, and the total annual R&D expenditure is about 1.2 billion yuan. There are more than 200 R&D projects, mainly covering innovative drugs, generic drugs and improved new drugs, first generic drugs and improved new drugs, etc. Among them, there are more than 50 new drugs under research with complete intellectual property rights, including 8 new macromolecular drugs, a total of 28 new drug projects have entered the clinical stage, and 11 varieties are currently undergoing Phase 2/3 clinical trials. A "complete, refined and sophisticated" product cluster has been built.
National major special research and development
Cumulative total investment cost
New drugs with complete intellectual property rights
New electronic materials
The research and development of HEC has created the industrialization of 8 series of products such as high-pressure formed foil, low-pressure formed foil, fluororesin material, new environmentally friendly refrigerant, energy storage material, electronic light foil, brazing foil, and hydrophilic foil for new electronic materials, and the product quality is excellent.
The research and development of HEC has brought about the industrialization of three series of products including oseltamivir phosphate, macrolide and benzbromarone.
Oseltamivir phosphate is currently the main drug of choice for the prevention and treatment of influenza in the world, and it is also a drug with excellent safety and efficacy for the treatment of influenza in children at this stage. HEC has an exclusive patent of the technology of Kewei granules suitable for children in the world until 2026, and both HEC Kewei Capsules and Kewei Granules have been included in the latest national B medical insurance drug list, so there is huge market potential and room for performance growth, and the final sales are expected to 10 billion.
The biochemical fermentation drug macrolide technology level and product quality are in the forefront of the world, and its output accounts for more than 65% of the world's standard market; its preparation product azithromycin has won the bid for more than 20 German insurance companies, and clarithromycin occupies more than 40% of the US market .
HEC already has a large health research institute with more than 200 high-end R&D talents. Adhering to the concept of safety, health and high technology, HEC has developed and industrialized Cordyceps sinensis and deep-processed products, food, health products, cosmetics, disinfection products and other high-quality health products. product.
Cordyceps sinensis is a rare nourishing treasure in China. Since 2007, HEC Group has carried out in-depth research on the ecological breeding technology of Cordyceps sinensis for 15 years, and has invested more than 4 billion yuan to build an intelligent ecological breeding base of nearly 400,000 square meters. It is the first in the world to realize the industrialization of ecological breeding of Cordyceps sinensis. The project has won the first prize of Guangdong Provincial Science and Technology Award, Hubei Provincial Patent Gold Award and many other honors, and has been highly recognized by the Ministry of Science and Technology, the Ministry of Industry and Information Technology and other ministries and commissions, as well as many industry experts and scholars. In order to meet the growing health needs of the people, it has launched three series of products: fresh cordyceps, freeze-dried cordyceps, and deep processing of cordyceps, and has strategically cooperated with Zhejiang Satellite TV to continuously title the "The Treasured Voice", investing over 100 million yuan every year, and continuing to increase brand building. With the continuous improvement of the industrialization barriers of ecological breeding technology and the implementation of brand strategy and national marketing channels, HEC will soon achieve the goal of over 10 billion in sales of Cordyceps sinensis.
HEC Research will focus on the three key areas of infection, tumor and metabolism in the future, and some projects are at the advanced level at home and abroad.
Global leader in the field of liver disease treatment at the forefront of the world：Relying on the State Key Laboratory of New Anti-Infective Drugs, the functional cure of hepatitis B is achieved through the combination of multiple targets. In the layout of the product line, 6 compounds with different mechanisms of action have been developed; Mofecidine is a brand-new hepatitis B virus capsid inhibitor. It has the potential to be the first in the world, is the compound with the fastest development in the world with the same target, and is also the world's first clinically proven small molecule compound that can clearly inhibit the s antigen; it has entered clinical phase 3 and will be listed around 2023. The annual sales are expected to reach 10 billion, to solve the major social needs in the field of hepatitis B. China's first completely self-developed new anti-hepatitis C drug, Emitasvir, has been launched in 2020. The drug for non-alcoholic steatohepatitis has entered clinical phase 2, and the effect among similar targets in the world is the more excellent.
China's advanced endocrine and metabolic therapy field coverage：A complete product pipeline including macromolecules and small molecules for the treatment of diabetes has been formed. The pipeline has expanded from simple hypoglycemic effects to cardiovascular benefits and even improvement of metabolic syndrome. The innovative targets take into account hypoglycemic, lipid-lowering, and NASH improvement. Targets under investigation cover insulin analogs, GLP1, FGF21, SGLT2, etc. Among them, the "First in class" project GLP1/FGF21 dual-target biological new drug with superior efficacy has taken the lead in entering the dual clinical research stage in China and Australia; Ifenidone, a new drug for idiopathic pulmonary fibrosis, has completed Phase 1 in China and the United States and entered Phase 2 clinical trials. It has the potential of "Best in class" and is expected to become a blockbuster new drug.
Unique and innovative tumor treatment solutions：Aiming at obvious clinical benefits, following the trend of tumor treatment, and based on molecular targeted drugs, the research and development of a full range of multi-level innovative products has been gradually expanded, and a diverse treatment plan covering tumor targeting, tumor immunity, and new biological therapy is created. Larotinib has entered clinical phase 3 and is expected to become the world's only small molecule new drug for the targeted treatment of esophageal cancer, and is expected to be launched in 2024; a new drug for the treatment of acute myeloid leukemia, Clifutinib, and is expected to be launched around 2025; new biological drugs have established multi-dimensional combination therapies such as antibodies, oncolytic viruses, and immune cells around gastrointestinal tumor-related targets.
HEC is one of China's advanced pharmaceutical companies with internationalized formulations, and has internationally advanced research and development capabilities for the first generic drugs in the United States, overseas generic drugs, and improved new drugs. HEC generic drugs have submitted 8 first generic drugs in the United States, 6 of which have been approved, a total of 31 varieties have been approved in the United States, and 28 varieties have been approved in the EU. Azithromycin tablets have won bids for more than 20 insurance companies in Germany, and clarithromycin tablets occupy more than 40% of the US market. HEC generic drugs have entered the international high-end generic drug market on a large scale. Relying on the mature international R&D system of generic drugs, we strive to create improved new drug series products with independent intellectual property rights, and have formed three international and improved new drug innovation platforms for oral solid preparations, long-acting injections and inhalation preparations.
HEC Research has established sales branches in 15 countries and regions including the United States, Germany, Japan, Australia, the United Kingdom, and South Korea.
Overseas biopharmaceuticals are progressing smoothly. Insulin glargine researched by HEC is expected to be launched in the United States in 2023, and insulin aspart will be launched in the United States in 2024. At that time, it will become the fourth company to list insulin in the United States after Novo Nordisk, Sanofi and Eli Lilly, and the first company in China to list insulin in the United States.
HEC Pharmaceutical Research Institute is actively promoting the IPO work. In 2021, the A round valuation will exceed 20 billion yuan, attracting investment from well-known institutions such as IDG Capital, Guangdong Hengjian, and Cinda Assets.
High-tech, R&D and innovation road
HEC unswervingly takes the road of high-tech, R&D and innovation, and will surely become a world-renowned company in China's top pharmaceutical and health industry.